tbuckley/cabot-search huggingface dataset:
Study Highlights Need for Expanded Access to Birth Control Beyond In-Person Visits
Authors: Samantha Anderer
Journal: JAMA (2024)

Anu Manchikanti Gomez, PhD; Ariana H. Bennett, DrPH; Alex Schulte, BA, BSPH; Jennet Arcara, PhD; Lisa Stern, MSN, MA; Angela D. Aina, MPH; Jamie Bardwell, MPP; Denicia Cadena, BA; Aisha Chaudhri, MA; Laura Davis, MA; Christine Dehlendorf, MD; Brittni Frederiksen, PhD; Elizabeth Jones, MPA; Megan L. Kavanaugh, DrPH; Catherine Labiran, MA; Raegan McDonald-Mosley, MD; Ellen Pliska, MHS; Whitney S. Rice, DrPH; Ena Suseth Valladares, MPH; Cassondra Marshall, DrPH
Mpox Vaccine Appears Safe for Use in Adolescents
Authors: Samantha Anderer
Journal: JAMA (2024)

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for use in the prevention of mpox and smallpox in adults. New research suggests it's also safe and produces an immune response in adolescents, a population affected by the current clade I mpox outbreak.
Neuropsychiatric diagnoses after montelukast initiation in paediatric patients with asthma
Authors: Tapio Paljarvi, Julian T Forton, Courtney Thompson, Sierra Luciano, Kimmo Herttua, Seena Fazel
Journal: Thorax (2024)

Background The evidence base on montelukast-associated adverse outcomes is inconclusive in children and young persons (CYP) with asthma. We aimed to investigate 1-year incidence of neuropsychiatric diagnoses after initiation of montelukast as an adjunct therapy to inhaled corticosteroids (ICSs) in CYP aged 3–17 years with asthma. Methods This propensity score matched cohort study was conducted using electronic health records between 2015 and 2019 in the TriNetX Analytics Network patient repository in the USA. Neuropsychiatric diagnoses were identified using the International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. We estimated risk ratios (RRs), absolute risk increase (ARI) and number needed to harm (NNH) with 95% CIs. Findings The mean age (SD) at index prescription in the 107 384 CYP with asthma was 8.7 (4.0) years (93 461 (87%) mild to moderate asthma; 62 301 (58%) male; 53 485 (50%) white; 33 107 (31%) black/African American). Montelukast was associated with excess incidence of any neuropsychiatric outcome (71 per 1000 persons with montelukast and 54 per 1000 persons with no montelukast; RR 1.32 (95% CI 1.25 to 1.39); ARI per 100 persons, 1.71 (95% CI 1.44 to 1.98); 1-year NNH, 58 patients (95% CI 51 to 69)). The highest excess risk in the montelukast group was for sleep disorders (RR 1.63 (95% CI 1.50 to 1.77); ARI per 100 persons 1.17 (95% CI 1.00 to 1.33); NNH, 85 patients (95% CI 75 to 100)). Montelukast use was also associated with excess incidence of anxiety disorders (RR 1.16 (95% CI 1.08 to 1.24)) and mood disorders (RR 1.16 (95% CI 1.05 to 1.29)). Conclusions In CYP with asthma who were treated with ICSs, adjunct treatment with montelukast was associated with a higher incidence of neuropsychiatric outcomes compared with those who were not exposed to montelukast.
Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Authors: Tom H. Karlsen, Kristin Kaasen Jørgensen, Annika Bergquist
Journal: Hepatology (2024)

It has proven difficult to establish robust evidence for significant clinical benefits of medical treatment in primary sclerosing cholangitis (PSC). For ursodeoxycholic acid, clinical practice guidelines only offer vague recommendations, leading to a situation of variable prescription rates depending on local reimbursement policies and physician preference. The difficulty in drug development in PSC is partly related to poor understanding of critical disease processes with failure to identify relevant mechanisms of action of putative drugs. The variable disease course, both intra-individually and between individuals, and lack of robust definitions of what success looks like for clinical trials in PSC have also contributed to the negative outcomes of trials performed. In this review article we will discuss these uncertainties and challenges, building on key previous and ongoing clinical trials. Despite the lack of consensus for an ideal phase II and phase III study design, several trials for diverse compounds are currently ongoing, indicating a shift from therapeutic nihilism towards hope for people with PSC. While waiting for robust efficacy data for drugs currently being tested, the current lack of effective interventions should not motivate prescription of compounds to people with PSC based on low-quality evidence.
DIAGNOSTIC AND PROGNOSTIC PERFORMANCE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN EOSINOPHILIC FASCIITIS: AN OBSERVATIONAL MULTICENTER RETROSPECTIVE STUDY
Authors: Kevin Chevalier, Jean-David Bouaziz, Matthieu Groh, Danièle Allali, Nabil Belfeki, Nellie Bourse, Claire Cazalets-Lacoste, Romain Collot, Edouard Flamarion, Valentin Lacombe, Tanguy Le Scornet, Wladimir Mauhin, Martin Michaud, Nicolas Dupin, Jean-Emmanuel Kahn, Luc Mouthon, Benjamin Chaigne
Journal: Journal of the American Academy of Dermatology (2024)
Tumor Upstaging in Invasive Melanoma is Associated with Changes in Clinical Management and Worse Prognosis
Authors: Amanda Rosenthal, Joyce Y Kim, Margit Lw Juhasz, Geena Conde, Clare Chen, Sarah Eng, Cristo A Carrasco Mendoza, Crystal T Chang, Iesha Ticknor, Leandra Doan, Kathyrn B Schwarzmann, Sarah Garzione, Yunjie Li, Zeuz A Islas, Nima M Gharavi, Jeremy R Man
Journal: Journal of the American Academy of Dermatology (2024)
Melatonin treatment increases skin microbiota-derived propionic acid to alleviate atopic dermatitis
Authors: Lan Yang, Piao Wang, Ting Gao, Xinyu Huang, Zhen Lin, Evan Sweren, Yue Li, Lu Chen, Martin P Alphonse, Jianglin Zhang, Gaofeng Wang
Journal: Journal of Allergy and Clinical Immunology (2024)
Abstract 3395: Potassium Supplement Use May Increase Hospitalization without Affecting Mortality in Chronic Heart Failure: Implications for Use of Aldosterone Antagonists to Maintain Potassium Balance in Chronic Heart Failure
Authors: Ali Ahmed, Chris Adamopoulos, Xuemei Sui, Thomas E Love
Journal: Circulation (2007)

Background: Hypokalemia is common in heart failure (HF). Aldosterone antagonists can raise serum potassium (K) and also improve survival. Yet, K-supplements are often used to correct hypokalemia; although little is known about the effects of K-supplements in HF. Methods: Of the 7788 ambulatory chronic HF patients in the Digitalis Investigation Group trial, 2199 (28%) were receiving K-supplements. Propensity scores for K-supplement use was calculated for each patient and were used to match 2131 patients receiving K-supplements with 2131 no-K-supplements patients (absolute standardized differences &lt;10% for all measured covariates). Matched Cox regression models were used to estimate effects of K-supplements on outcomes during 40 months of median follow-up. Results: Compared with 68% (rate, 4120/10000 person-years) of no-K-supplement patients, 71% (rate, 4777/10000 person-years) of patients receiving K-supplements were hospitalized from all causes (hazard ratio, 1.15; 95% CI, 1.05–1.26; P=0.004). Compared with 38% (rate, 1313/10000 person-years) of no-K-supplement patients, 38% (rate, 1327/10000 person-years) of patients receiving K-supplements died from all causes (hazard ratio, 1.05; 95% CI, 0.94–1.18; P=0.390). Conclusion: K-supplement use was associated with no mortality reduction but increased hospitalization. This first report on the effect of K-supplement in HF raises question about the wisdom of K-supplement use to correct hypokalemia and maintain normokalemia in HF. Given the proven mortality benefits of aldosterone antagonists and their ability to raise serum K, spironolactone may be preferable to maintain normokalemia in chronic HF. Figure 1. Association of potassium supplement use and all-cause hospitalization
State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the <scp>ESC</scp>, the <scp>ESC</scp> Council on Cardiovascular Genomics and the <scp>ESC</scp> Working Group on Myocardial &amp; Pericardial Diseases
Authors: Sophie Van Linthout, Konstantinos Stellos, Mauro Giacca, Edoardo Bertero, Antonio Cannata, Lucie Carrier, Pablo Garcia‐Pavia, Alessandra Ghigo, Arantxa González, Kristina H. Haugaa, Massimo Imazio, Luis R. Lopes, Patrick Most, Piero Pollesello, Heribert Schunkert, Katrin Streckfuss‐Bömeke, Thomas Thum, Carlo Gabriele Tocchetti, Carsten Tschöpe, Peter van der Meer, Eva van Rooij, Marco Metra, Giuseppe M.C. Rosano, Stephane Heymans
Journal: European Journal of Heart Failure (2024)
LIFU-unlocked Endogenous H2S Generation for Enhancing Atherosclerosis-specific Gas-enzymatic Therapy
Authors: Hongjin An, Xiaoling Qiu, Xiaoting Wang, Chier Du, Xun Guo, Shengzhe Hou, Min Xu, Jingxue Wang, Chen Cheng, Haitao Ran, Pan Li, Zhigang Wang, Zhiyi Zhou, Jianli Ren, Weixi Jiang
Journal: Biomaterials (2024)
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death
Authors: Giuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia, Marco Enea, Gabriele Di Maria, Alessandro Grova, Roberta Ciccia, Giulia F. Manfredi, Massimo Iavarone, Arndt Vogel, Amit G. Singal, Maria Reig, David J. Pinato, Calogero Cammà
Journal: Clinical Cancer Research (2024)

Abstract Purpose: The prognosis of patients with unresectable hepatocellular carcinoma (uHCC) and compensated cirrhosis is influenced by cancer progression. Data on the incidence and the prognostic role of clinical hepatic decompensation following immune checkpoint inhibitor therapy are lacking. We aimed to assess whether early clinical hepatic decompensation (CHD) within 3 months from commencement of systemic therapy affects overall survival (OS) of patients treated with Atezolizumab plus Bevacizumab or Sorafenib. Patients and Methods: Individual patient data from IMbrave150 trial were analyzed. Cumulative incidence of CHD was assessed by competing risks analysis against HCC radiological progression. Early CHD and HCC radiological progression were assessed as predictors of OS by time-dependent Cox model. Results: The 3- and 12-month rates of CHD were 7% and 12%, respectively, while the 3- and 12-month rates of HCC radiological progression were 23% and 52%. Albumin-bilirubin(ALBI)grade 2 (Sub-distribution hazard ratio[sHR] 1.79, 95%CI 1.01-3.19, p=0.049), INR(sHR 1.97, 95%CI 1.64-2.37, p&amp;lt;0.001) and presence of neoplastic macrovascular invasion (sHR 2.01, 95%CI 1.14-3.54, p=0.020) were independently associated with higher risk of CHD. Early CHD(HR 7.56, 95%CI 4.47-12.8) and early HCC radiological progression(HR 5.92, 95%CI 4.03-8.69), as first events, were independently associated with higher mortality. Conclusions: This study provides robust evidence that early CHD is associated with the highest risk of death in patients with uHCC undergoing systemic treatment. Within well-compensated participants, ALBI, INR and macrovascular invasion identify a population at higher risk of decompensation. Inclusion of clinical decompensation events in future prospective clinical trials may improve characterization of OS from systemic therapy of HCC.
Evaluation of artificial intelligence in the therapy of oropharyngeal squamous cell carcinoma - De-escalation via Claude 3 Opus, Vertex AI and ChatGPT 4.0? – An experimental study
Authors: Benedikt Schmidl, Tobias Hütten, Steffi Pigorsch, Fabian Stögbauer, Cosima C. Hoch, Timon Hussain, Barbara Wollenberg, Markus Wirth
Journal: International Journal of Surgery (2024)

Schmidl, Benedikt; Hütten, Tobias PD; Pigorsch, Steffi PD; Stögbauer, Fabian; Hoch, Cosima C. PD; Hussain, Timon; Wollenberg, Barbara PD; Wirth, Markus Author Information
Heterogeneity of tumor-infiltrating T cells and its impact on anti-PD-1/PD-L1 immunotherapy: insights from integrated multi-cancer single-cell and bulk transcriptomic analysis
Authors: Kai Kang, Chang Han, Li Wang, Ailin Zhao, Yijun Wu
Journal: International Journal of Surgery (2024)

Kang, Kai MD; Han, Chang MD; Wang, Li MD; Zhao, Ailin MD; Wu, Yijun MD Author Information
Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer
Authors: Mehmet Altan, Gilberto Lopes, T. Jeroen N. Hiltermann, Ramaswamy Govindan, Liza C. Villaruz, Emiliano Calvo, Martin J. Edelman, Muhammad Furqan, Joel Neal, Enriqueta Felip, Jennifer W. Carlisle, John V. Heymach, Róisín Eilish. O'Cearbhaill, Marjorie Zauderer, Michael Chisamore, Ellie Corigliano, Ioanna Eleftheriadou, Stefan Zajic, Ben Jenkins, Sophia Goodison, Sunil Suchindran, Natalia Ramos-Hernandez, Nidale Tarek, Adam J. Schoenfeld
Journal: Clinical Cancer Research (2024)

Abstract Purpose: To evaluate safety, tolerability, and anti-tumor response of lete-cel, genetically modified autologous T-cells expressing a T-cell receptor specific for NY-ESO-1/LAGE-1a shared epitope, alone or in combination with pembrolizumab, in human leukocyte antigen HLA-A*02-positive (HLA-A*02:01-, HLA-A*02:05-, and/or HLA-A*02:06-) patients with New York esophageal squamous cell carcinoma 1 (NY-ESO-1)- and/or LAGE-1a-positive non-small cell lung cancer (NSCLC). Experimental Design: Study 208749 was a single-arm study of lete-cel alone. Study 208471 was a multi-arm study of lete-cel alone or in combination with pembrolizumab in patients with advanced or recurrent NSCLC. Results: Over 2500 patients were screened for target expression. In the multi-arm study, 738 (45%) of 1638 tested patients were HLA-A*02-positive. NY-ESO-1 and LAGE-1a testing was positive in 12% (62/525) and 4% (15/348) of tested patients, respectively. Forty-one patients positive for HLA-A*02 and antigen expression were screened in the single-arm study. Overall, 43 patients underwent leukapheresis and 18 received lete-cel across studies. Lete-cel demonstrated a manageable safety profile. No fatal treatment-related serious adverse events (AEs) were reported in either study. Cytopenias and cytokine release syndrome were the most common treatment-emergent AEs. Combining pembrolizumab with lete-cel did not appear to increase toxicity over lete-cel alone. Limited anti-tumor activity was observed; one of 18 patients had a durable response persisting for 18 months. Pharmacokinetic data showed similar T-cell expansion in all patients. Conclusions: Extensive HLA-A*02 and antigen expression testing was performed to identify potential participants. Lete-cel was generally well tolerated and had no unexpected AEs. Anti-tumor activity was observed in a limited number of patients.
A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer
Authors: Randy F. Sweis, Gurkamal S. Chatta, Rohit K. Jain, Helen Moon, Scott Edward. Delacroix, Alana Fang, Leonard D’Amico, Angela Shaulov. Kask, Martin A. Cheever, Steven Fling, Elad Sharon, Andreanne Lacroix, Judith C. Kaiser, Russell K. Pachynski, Evan Y. Yu
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Advanced urothelial cancer generally has high mortality despite modern anti-PD-1/L1 antibody-based combinations. Augmenting checkpoint inhibitor-mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (CITN-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses. Patients and Methods: Patients with urothelial cancer following platinum chemotherapy were randomized to atezolizumab alone or with CYT107 weekly for four doses. The primary objective was clinical efficacy by objective response rate (ORR). Secondary objectives included safety, toxicity, and other clinical outcomes. Correlative endpoints included peripheral immunophenotyping and quantification of cytokines. Results: CYT107 plus atezolizumab was well-tolerated, without dose-limiting toxicities (DLTs), and lower grade 3-4 treatment-related adverse events (TRAEs) compared to atezolizumab. The ORR was 26.3% for the combination versus 23.8% for atezolizumab alone (p = 0.428). The complete response (CR) rate was 10.5% for the combination versus 4.8% for monotherapy. Three patients on the combination had responses &amp;gt;21 months versus one with monotherapy. CD4+ and CD8+ T lymphocyte expansion occurred in patients with response to combination therapy, with the greatest effect in T memory stem cell (Tscm) cells. Responding patients had elevated baseline CCL4 and decreased VEGF-A and TNF. Conclusions: Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the CR rate, and durable responses exceeding 2 years, however, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.
Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer
Authors: Cristiano Ferrario, John Mackey, Karen A. Gelmon, Nathalie Levasseur, Poul H. Sorensen, Htoo Z. Oo, Gian L. Negri, Veronica W. L. Tse, Sandra E. Spencer, Grace Cheng, Gregg B. Morin, Sonia del Rincon, Tiziana Cotechini, Christophe Gonçalves, Charles C.T. Hindmarch, Wilson H. Miller, Mehdi Amiri, Tayebeh Basiri, Victor Villareal-Corpuz, Sam Sperry, Kevin Gregorczyk, Gonzalo Spera, Nahum Sonenberg, Michael Pollak
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Preclinical data motivate clinical evaluation of inhibitors of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2). We conducted a phase 1b clinical trial to study target engagement and safety of tomivosertib, a MNK1/2 inhibitor, alone and in combination with paclitaxel. Methods: Eligible patients had metastatic breast cancer resistant to standard of care treatments. Biopsies were obtained at baseline and during treatment with tomivosertib, and then tomivosertib was continued with addition of paclitaxel until disease progression or toxicity. Serum drug levels were measured, and pharmacodynamic endpoints included immunohistochemistry, proteomics, translatomics, and imaging mass cytometry. Results: Tomivosertib alone and in combination with paclitaxel was well tolerated. There was no pharmacokinetic interaction between the drugs. We observed a clear reduction in phosphorylation of eIF4E at S209, a major substrate of MNK1/2, and identified tomivosertib-induced perturbations in the proteome, translatome, and cellular populations of biopsied metastatic breast cancer tissue. Conclusion: We conclude that tomivosertib effectively inhibits MNK1/2 activity in metastatic breast cancer tissue, and that it can safely be combined with paclitaxel in future phase II studies. We demonstrate feasibility of using proteomic profiles, translatomic profiles, and spatial distribution of immune cell infiltrates for clinical pharmacodynamic studies.
CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival
Authors: Gerardo Ferrer, Florencia Palacios, Pui Yan Chiu, Kelly Wong, Alberto Bueno-Costa, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Shih-Shih Chen, Barbara Sherry, Nicholas Chiorazzi
Journal: Leukemia (2024)
Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study.
Authors: Sofía De La Villa, Francesc Escrihuela-Vidal, Nuria Fernández-Hidalgo, Rosa Escudero-Sánchez, Itxasne Cabezón, Lucía Boix-Palop, Beatriz Díaz-Pollán, Ane Josune Goikoetxea, María José García-País, María Teresa Pérez-Rodríguez, Ángela Crespo, Luis Buzón-Martín, Oscar Sanz-Peláez, Lucía Ramos-Merino, Fiorana Silvante, Patricia Muñoz
Journal: Clinical Microbiology and Infection (2024)
Diagnosing infectious encephalitis: a Narrative review
Authors: Sabine E Olie, Steven L Staal, Diederik van de Beek, Matthijs C Brouwer
Journal: Clinical Microbiology and Infection (2024)

Diagnosing infectious encephalitis can be challenging as it can be caused by a wide range of pathogens, with viruses being the most common cause. In a substantial number of patients, no pathogen is identified despite a clinical diagnosis of infectious encephalitis. Recent advancements in diagnostic testing have introduced new methods to address this diagnostic challenge and improve pathogen detection.
Inhibition of Mitochondrial Bioenergetics and Hypoxia to Radiosensitize Diffuse Intrinsic Pontine Glioma
Authors: Han Shen, Faiqa Mudassar, Shiyong Ma, Xingyu Wang, Sandy Nguyen, Neha Bal, Quy-Susan Huynh, Dongwei Wang, Cecilia Chang, Prunella Ing, Winny Varikatt, Joey Lai, Brian Gloss, Jeff Holst, Geraldine M O’Neill, Harriet Gee, Kristina M Cook, Eric Hau
Journal: Neuro-Oncology (2024)

Abstract Background Diffuse intrinsic pontine gliomas (DIPGs) and other H3K27M-mutated diffuse midline gliomas (DMGs) are brain tumors that primarily affect children. Radiotherapy is the standard of care but only provides only temporary symptomatic relief due to radioresistance. Although hypoxia is a major driver of radioresistance in other tumors, there is no definitive evidence that DIPGs are hypoxic. Diffuse intrinsic pontine gliomas often contain histone mutations, which alter tumor metabolism and are also associated with radioresistance. Our objective was to identify the metabolic profiles of DIPG cells, detect hypoxia signatures, and uncover metabolism-linked mechanisms of radioresistance to improve tumor radiosensitivity. Methods Using DIPG models combined with clinical datasets, we examined mitochondrial metabolism and signatures of hypoxia. We explored DIPG reliance on mitochondrial metabolism using extracellular flux assays and targeted metabolomics. In vitro and in vivo models were used to explore the mechanisms of targeting mitochondrial bioenergetics and hypoxia for radiosensitization. Treatment-induced transcriptomics and metabolomics were also investigated. Results Comprehensive analyses of DIPG cells show signatures of enhanced oxidative phosphorylation (OXPHOS). We also identified increased expression of specific OXPHOS-related genes and signatures of hypoxia gene expression in datasets obtained from DIPG patients. We found the presence of hypoxia in orthotopic mouse models bearing DIPG tumors. These findings enabled us to develop a proof-of-concept treatment strategy to enhance radiosensitivity of DIPGs in vitro and in animal models. Conclusions Diffuse intrinsic pontine glioma cells rely on mitochondrial metabolism for growth, and targeting mitochondria disrupts bioenergetics, alleviates hypoxia, and enhances radiosensitivity. These findings warrant further exploration of OXPHOS inhibition as a radiosensitizing strategy for DIPG treatment.
Subconjunctival injection of microcrystalline prodrug of dexamethasone for long-acting anti-inflammation after phacoemulsification surgery
Authors: Xueyan Zhou, Zunkai Xu, Yanliang Dong, Maoyu Cai, Zhixia Chen, Jingqing Mu, Bo Yuan, Xia Hua, Xiaoyong Yuan, Shutao Guo
Journal: Journal of Controlled Release (2024)
“Target Trial Emulation” for Observational Studies — Potential and Pitfalls
Authors: Rebecca A Hubbard, Constantine A Gatsonis, Joseph W Hogan, David J Hunter, Sharon-Lise T Normand, Andrea B Troxel
Journal: New England Journal of Medicine (2024)

To improve the quality of observational studies, target trial emulation requires careful specification of design elements, analytic methods for addressing confounding, and reporting of sensitivity analyses.
Transcatheter Tricuspid Valve Replacement
Authors: Jörg Hausleiter, Lukas Stolz, Philipp Lurz, Volker Rudolph, Rebecca Hahn, Rodrigo Estévez-Loureiro, Charles Davidson, Firas Zahr, Susheel Kodali, Raj Makkar, Anson Cheung, Renato D Lopes, Francesco Maisano, Neil Fam, Azeem Latib, Stephan Windecker, Fabien Praz
Journal: Journal of the American College of Cardiology (2024)